Other equities research analysts also recently issued reports about the company. Zacks Investment Research upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $130.00 price target for the company in a research note on Wednesday, May 8th. Piper Jaffray Companies cut their price target on Sarepta Therapeutics from $208.00 to $185.00 and set an “overweight” rating for the company in a research note on Tuesday, August 20th. Royal Bank of Canada lowered their price objective on Sarepta Therapeutics to $204.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 20th. William Blair reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Friday, August 9th. Finally, Needham & Company LLC lowered their price objective on Sarepta Therapeutics from $196.00 to $170.00 and set a “buy” rating on the stock in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $197.78.
Shares of NASDAQ:SRPT traded up $0.20 on Wednesday, hitting $88.18. 9,264 shares of the company traded hands, compared to its average volume of 2,244,961. Sarepta Therapeutics has a 52 week low of $83.62 and a 52 week high of $165.87. The stock has a 50 day simple moving average of $115.87 and a 200-day simple moving average of $125.74. The company has a market cap of $6.77 billion, a PE ratio of -16.20 and a beta of 2.19. The company has a quick ratio of 7.84, a current ratio of 8.81 and a debt-to-equity ratio of 0.44.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($3.74) EPS for the quarter, missing the consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative return on equity of 55.37% and a negative net margin of 165.52%. The business had revenue of $94.67 million during the quarter, compared to the consensus estimate of $91.05 million. During the same quarter in the previous year, the business posted ($1.67) earnings per share. Sarepta Therapeutics’s quarterly revenue was up 28.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post -4.94 earnings per share for the current year.
In other Sarepta Therapeutics news, Director Richard Barry purchased 1,300 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $122.50 per share, with a total value of $159,250.00. Following the acquisition, the director now directly owns 3,173,365 shares of the company’s stock, valued at $388,737,212.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Douglas S. Ingram purchased 16,252 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were acquired at an average cost of $123.07 per share, with a total value of $2,000,133.64. Following the completion of the acquisition, the chief executive officer now directly owns 424,405 shares in the company, valued at $52,231,523.35. The disclosure for this purchase can be found here. Insiders acquired a total of 30,752 shares of company stock valued at $3,502,664 over the last quarter. Company insiders own 6.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Evolution Wealth Advisors LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $25,000. Trust Co. of Vermont raised its stake in Sarepta Therapeutics by 2,125.0% during the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 170 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $32,000. BSW Wealth Partners purchased a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $52,000. Finally, Coastal Investment Advisors Inc. raised its stake in Sarepta Therapeutics by 57.4% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 425 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 155 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Read More: Trade War
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.